Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

November 2014 - FRMC

11/14/2014
Once again, HCV is at the forefront of discussions as the FDA just recently approved the first once-daily oral combination of ledipasvir and sofosbuvir to treat HCV genotype 1 infection, which comes with an even larger pricetag: $94,500 for a...
Once again, HCV is at the forefront of discussions as the FDA just recently approved the first once-daily oral combination of ledipasvir and sofosbuvir to treat HCV genotype 1 infection, which comes with an even larger pricetag: $94,500 for a...
Once again, HCV is at the...
11/14/2014
First Report Managed Care

Advertisement

Advertisement

Advertisement